SCHEMBL4871870

SCHEMBL4871870

CNC(=S)N1CCCCc2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.57
ALDH1A1 P00352 7/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
LMNA P02545 1/20 0.57
GAA P10253 4/20 0.56
MGLL Q99685 1/20 0.56
MAPK1 P28482 1/20 0.55
NOTUM Q6P988 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
SIGMAR1 Q99720 1/20 0.53
HPGD P15428 2/20 0.52
HTT P42858 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
AVPR1A P37288 1/20 0.50
KDM4E B2RXH2 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867047 0.82 MEN1 (0.73) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL4867294 0.81 NOTUM (0.62) MAPTMEN1KMT2ALMNANOTUM
SCHEMBL173546 0.79 GAA (0.60) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL4869697 0.79 TP53 (0.58) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL9799093 0.76 NOTUM (0.69) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL29941498 0.76 MGLL (0.62) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL30204132 0.76 NOTUM (0.69) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL5423105 0.76 NOTUM (0.90) MAPTALDH1A1MEN1KMT2ANOTUM
SCHEMBL4868428 0.76 THRB (0.64) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL4869536 0.76 KMT2A (0.59) MAPTALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885ALDH1A1 3990/4885MEN1 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.